David S – AKL

AKL > Articles by: David S

New Senomorphic Patent Filed

Senescence is a process in which ageing cells stop dividing and is involved in many diseases of ageing. Over time senescent cells build up in tissues and release harmful substances causing inflammation and damage to healthy cells. The development of OA correlates with a rise in the number of senescent cells in joint tissues. Laboratory […]

OARSI 2023 Presentation

AKL’s data on the effect of APPA in reducing cellular senescence in articular chondrocytes conducted by INIBIC (Instituto de Investigación Biomédica de A Coruña) has been accepted for publication at OARSI 2023, the leading global osteoarthritis conference being held in Denver, Colorado. Copy of the abstract will be available at the time of the conference. […]

Phase 2a Human Trial Key Findings

AKL has completed analysis of a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee. The data from this Phase 2a trial adds considerably to our understanding of APPA. The trial was designed to assess the efficacy of APPA in subjects with varying degrees of osteoarthritis and, in predefined […]

EULAR & OARSI 2022 Presentations

AKL’s data on APPA’s Phase IIa Human Clinical Trial, ‘The Efficacy & Safety of APPA in Symptomatic Knee Osteoarthritis’, was presented as a scientific abstract and as a poster at the congress for European Alliance of Associations for Rheumatology (EULAR) 2022. The APPA phase IIa trial was designed to assess the efficacy of APPA in […]

Senescence Research in APPA with INIBIC

AKL has agreed a further collaboration with the Institute of Biomedical Research of A Coruña (INIBIC) to advance the understanding of APPA’s mechanism of action. INIBIC is Spain’s leading biomedical research institution. Previous research at INIBIC has shown that APPA has a significant effect on senescent cells in human chondrocytes1 – see BMJ abstract. This […]

MHRA awards Innovation Passport for APPA in Osteoarthritis